The Monkeypox (Mpox) Diagnosis Market involves the diagnosis of Monkeypox disease through tests and kits. The disease is caused by the Monkeypox virus which is part of the Orthopoxvirus genus. Monkeypox can spread to humans through close contact with an infected person or animal, or with material contaminated with the virus. The virus enters the body through broken skin, respiratory tract, or the mucous membranes (eyes, nose, or mouth). Once inside the body, it uses the immune cells as vehicles and travels through the lymph system to other organs. Common symptoms include fever, headache, muscle aches, backache, swollen lymph nodes, chills, and exhaustion. Rashes or sores may appear on the face, inside the mouth, and other parts of the body, especially the hands, feet, chest, genitals, or anus.

The global Monkeypox (Mpox) Diagnosis Market Demand is driven by increasing awareness about orthopoxvirus infections like Monkeypox. The sudden rise in cases across multiple non-endemic countries has led to more screening programs being implemented worldwide. Diagnostic technologies play a key role in confirming suspected cases and controlling the spread of the disease.

Global monkeypox (Mpox) diagnosis market is estimated to be valued at USD 1.97 Bn in 2024 and is expected to reach USD 2.62 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.2% from 2024 to 2031.

Key Takeaways
Key players operating in the Monkeypox (Mpox) Diagnosis market are Aegis Sciences Corporation, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Sonic Healthcare Limited, QIAGEN, Mayo Clinic Laboratories, Chembio Diagnostics, Inc., Sonora Quest Laboratories, Thermo Fisher Scientific, BD (Becton, Dickinson and Company), CerTest Biotech, GenMark Diagnostics, Inc., Roche Diagnostics, Abbott Laboratories, Hologic, Inc., Siemens Healthineers, PerkinElmer, Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., and Meridian Bioscience, Inc.

Get More Insights on- Monkeypox (Mpox) Diagnosis Market